bioAffinity Technologies, Inc. (Nasdaq: BIAF) announced on September 3, 2026, that President and CEO Maria Zannes will represent the company at the H.C. Wainwright 28th Annual Global Investment Conference. The event is scheduled to take place from September 14 to September 16, 2026.
During the conference, Ms. Zannes will deliver a corporate update and engage in one-on-one meetings with institutional investors. The presentation is expected to cover recent and upcoming strategic milestones, as well as the commercial adoption and momentum of the Company’s CyPath Lung diagnostic test. Additionally, the update will include information regarding advancements for the proprietary technology platform intended to develop additional diagnostic and therapeutic applications.
A live and archived webcast of the presentation will be available on September 11, accessible via a link provided on the company’s website.
As of September 2, 2026, bioAffinity reported 600,736 outstanding shares of common stock. Based on the closing price of the stock on the Nasdaq Capital Market on that date, the aggregate market value of the common stock was approximately $5.9 million.
The Company’s primary product, CyPath Lung, is a noninvasive test marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services. The test is designed for the detection of early-stage lung cancer.
